MC
BIO icon

Martin & Co’s Bio-Rad Laboratories Class A BIO Stock Holding History

Martin & Co’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,012
Closed -$2.11M – 118
2020
Q1 		$2.11M Buy
6,012
+205
+4% +$75.4K 0.75% 42
2019
Q4 		$2.15M Buy
5,807
+70
+1% +$24.7K 0.62% 56
2019
Q3 		$1.91M Buy
5,737
+77
+1% +$25.1K 0.58% 65
2019
Q2 		$1.77M Buy
5,660
+35
+0.6% +$10.5K 0.53% 73
2019
Q1 		$1.72M Buy
5,625
+240
+4% +$64.8K 0.52% 73
2018
Q4 		$1.25M Sell
5,385
-5
-0.1% -$1.34K 0.44% 90
2018
Q3 		$1.69M Sell
5,390
-25
-0.5% -$7.76K 0.51% 76
2018
Q2 		$1.56M Buy
5,415
+20
+0.4% +$5.52K 0.5% 80
2018
Q1 		$1.35M Sell
5,395
-490
-8% -$125K 0.45% 90
2017
Q4 		$1.41M Hold
5,885
– – 0.45% 89
2017
Q3 		$1.31M Sell
5,885
-940
-14% -$212K 0.43% 95
2017
Q2 		$1.54M Buy
6,825
+40
+0.6% +$8.72K 0.48% 86
2017
Q1 		$1.35M Buy
6,785
+15
+0.2% +$2.89K 0.43% 82
2016
Q4 		$1.23M Buy
6,770
+20
+0.3% +$3.41K 0.4% 81
2016
Q3 		$1.11M Buy
6,750
+85
+1% +$12.9K 0.36% 81
2016
Q2 		$953K Buy
6,665
+1,790
+37% +$255K 0.31% 91
2016
Q1 		$667K Buy
4,875
+175
+4% +$23K 0.21% 96
2015
Q4 		$652K Hold
4,700
– – 0.21% 83
2015
Q3 		$631K Buy
4,700
+275
+6% +$39.6K 0.21% 80
2015
Q2 		$666K Hold
4,425
– – 0.22% 77
2015
Q1 		$598K Hold
4,425
– – 0.19% 78
2014
Q4 		$533K Buy
4,425
+100
+2% +$11.5K 0.17% 86
2014
Q3 		$490K Buy
4,325
+50
+1% +$5.92K 0.16% 84
2014
Q2 		$512K Buy
4,275
+150
+4% +$18.3K 0.17% 84
2014
Q1 		$528K Hold
4,125
– – 0.18% 80
2013
Q4 		$510K Buy
4,125
+100
+2% +$12.2K 0.17% 84
2013
Q3 		$473K Buy
4,025
+50
+1% +$5.9K 0.17% 85
2013
Q2 		$446K Buy
+3,975
New +$466K 0.16% 86

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Martin & Co's BIO Position: Q2 2020 in Review

Martin & Co sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2020, closing a stake of 6,012 shares — an estimated $2.11M sold.

Martin & Co first reported a position in BIO in Q2 2013 and held it in 28 quarters. The position peaked at $2.15M in Q4 2019. 470 funds tracked by Wall St. Rank hold BIO as of Q2 2020.

  • Martin & Co reported no remaining Bio-Rad Laboratories Class A position as of Q2 2020 after selling out during the quarter.
  • Martin & Co sold 6,012 Bio-Rad Laboratories Class A shares in Q2 2020, an estimated $2.11M.
  • Martin & Co first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 28 quarters.
  • Martin & Co's Bio-Rad Laboratories Class A position peaked at $2.15M in Q4 2019.
  • 470 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2020.

Based on Martin & Co's 13F filing for Q2 2020, filed 14 Aug 2020.